210 related articles for article (PubMed ID: 9621276)
21. Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD).
Belibi F; Zafar I; Ravichandran K; Segvic AB; Jani A; Ljubanovic DG; Edelstein CL
Am J Physiol Renal Physiol; 2011 May; 300(5):F1235-43. PubMed ID: 21270095
[TBL] [Abstract][Full Text] [Related]
22. The Endothelin system in polycystic kidneys of Han:SPRD rats.
Hocher B; Zart R; Braun N; Schwarz A; van der Woude F; Rohmeiss P; Koppenhagen K
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S342-4. PubMed ID: 9595476
[TBL] [Abstract][Full Text] [Related]
23. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?
Edelstein CL
Cell Cycle; 2005 Nov; 4(11):1550-4. PubMed ID: 16258272
[TBL] [Abstract][Full Text] [Related]
24. The effect of paclitaxel on the progression of polycystic kidney disease in rodents.
Martinez JR; Cowley BD; Gattone VH; Nagao S; Yamaguchi T; Kaneta S; Takahashi H; Grantham JJ
Am J Kidney Dis; 1997 Mar; 29(3):435-44. PubMed ID: 9041221
[TBL] [Abstract][Full Text] [Related]
25. Focal overexpression of collagen IV characterizes the initiation of epithelial changes in polycystic kidney disease.
Schäfer K; Bader M; Gretz N; Oberbäumer I; Bachmann S
Exp Nephrol; 1994; 2(3):190-5. PubMed ID: 7922272
[TBL] [Abstract][Full Text] [Related]
26. Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease.
Zhang Y; Reif G; Wallace DP
Cell Signal; 2020 Aug; 72():109646. PubMed ID: 32311505
[TBL] [Abstract][Full Text] [Related]
27. Autosomal-dominant polycystic kidney disease in the rat.
Cowley BD; Gudapaty S; Kraybill AL; Barash BD; Harding MA; Calvet JP; Gattone VH
Kidney Int; 1993 Mar; 43(3):522-34. PubMed ID: 8455352
[TBL] [Abstract][Full Text] [Related]
28. Global gene expression profiling in early-stage polycystic kidney disease in the Han:SPRD Cy rat identifies a role for RXR signaling.
Kugita M; Nishii K; Morita M; Yoshihara D; Kowa-Sugiyama H; Yamada K; Yamaguchi T; Wallace DP; Calvet JP; Kurahashi H; Nagao S
Am J Physiol Renal Physiol; 2011 Jan; 300(1):F177-88. PubMed ID: 20926632
[TBL] [Abstract][Full Text] [Related]
29. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
30. Altered organic anion and osmolyte content and excretion in rat polycystic kidney disease: an NMR study.
Ogbron MR; Sareen S; Prychitko J; Buist R; Peeling J
Am J Physiol; 1997 Jan; 272(1 Pt 2):F63-9. PubMed ID: 9039050
[TBL] [Abstract][Full Text] [Related]
31. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Nagao S; Yamaguchi T; Kusaka M; Maser RL; Takahashi H; Cowley BD; Grantham JJ
Kidney Int; 2003 Feb; 63(2):427-37. PubMed ID: 12631108
[TBL] [Abstract][Full Text] [Related]
32. Differentiation and cell polarity during renal cyst formation in the Han:SPRD (cy/+) rat, a model for ADPKD.
Obermüller N; Gretz N; Kriz W; van der Woude FJ; Reilly RF; Murer H; Biber J; Witzgall R
Am J Physiol; 1997 Sep; 273(3 Pt 2):F357-71. PubMed ID: 9321908
[TBL] [Abstract][Full Text] [Related]
33. Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats.
Aukema HM; Housini I
Kidney Int; 2001 Jan; 59(1):52-61. PubMed ID: 11135057
[TBL] [Abstract][Full Text] [Related]
34. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats.
Cowley BD; Rupp JC; Muessel MJ; Gattone VH
Am J Kidney Dis; 1997 Feb; 29(2):265-72. PubMed ID: 9016899
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease.
Nagao S; Kusaka M; Nishii K; Marunouchi T; Kurahashi H; Takahashi H; Grantham J
J Am Soc Nephrol; 2005 Jul; 16(7):2052-62. PubMed ID: 15888569
[TBL] [Abstract][Full Text] [Related]
36. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation.
Wu M; Gu J; Mei S; Xu D; Jing Y; Yao Q; Chen M; Yang M; Chen S; Yang B; Qi N; Hu H; Wüthrich RP; Mei C
Nephrol Dial Transplant; 2016 Nov; 31(11):1826-1834. PubMed ID: 27190325
[TBL] [Abstract][Full Text] [Related]
37. Urinary biomarkers for monitoring disease progression in the Han:SPRD-cy rat model of autosomal-dominant polycystic kidney disease.
Wiedmeyer CE; Royal AB
Comp Med; 2010 Dec; 60(6):448-54. PubMed ID: 21262131
[TBL] [Abstract][Full Text] [Related]
38. The pathogenesis of polycystic kidney disease.
Carone FA; Bacallao R; Kanwar YS
Histol Histopathol; 1995 Jan; 10(1):213-21. PubMed ID: 7756739
[TBL] [Abstract][Full Text] [Related]
39. Hereditary error in epidermal growth factor prohormone metabolism in a rat model of autosomal dominant polycystic kidney disease.
Lakshmanan J; Eysselein V
Biochem Biophys Res Commun; 1993 Dec; 197(3):1083-93. PubMed ID: 8280123
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
